Treatment of metastatic castration-resistant prostate cancer with niraparib

The present invention relates to a method of improving the efficacy of a treatment of 2 + line metastatic castration resistant prostate cancer (mCRPC) with a biallele DNA repair anomaly selected from the group consisting of: i) BRCA (BRCA1, BRCA2, or a combination thereof), ii) non-BRCA (ATM, FANCA, PALB2, CHEK2, BRIP1, HDAC2, or any combination thereof); or iii) any combination thereof; wherein the male human has received past taxane-based chemotherapy and androgen receptor (AR) targeted therapy; the method of improving the efficacy of a treatment comprises administering to the male human 300 mg of niraparib orally administered once a day. 本发明涉及在男性人类中改善具有双等位基因DNA修复异常的2+线转移性去势抵抗性前列腺癌(mCRPC)的治疗功效的方法，其中所述双等位基因DNA修复异常选自：i)BRCA(BRCA1、BRCA2或它们的组合)，ii)非BRCA(ATM、FANCA、PALB2、CHEK2、BRIP1、HDAC2或它们的任何组合)；或iii)它们的任何组合；其中该男性人类已接受既往的基于紫杉烷的化疗和雄激素受体(AR)靶向疗法；所述改善治疗功效的方法包括向所述男性人类施用每日一次口服给药的300mg尼拉帕尼。